These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 6661513)

  • 1. Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.
    Lee JK; Paine MF; Brouwer KL
    J Pharmacol Exp Ther; 2010 Aug; 334(2):410-8. PubMed ID: 20430841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.
    Friedman GD; Udaltsova N; Chan J; Quesenberry CP; Habel LA
    Cancer Causes Control; 2009 Dec; 20(10):1821-35. PubMed ID: 19582585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of sulindac. A dynamic old drug.
    Davies NM; Watson MS
    Clin Pharmacokinet; 1997 Jun; 32(6):437-59. PubMed ID: 9195115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs. Do they have advantages in clinical practice?
    Stella VJ; Charman WN; Naringrekar VH
    Drugs; 1985 May; 29(5):455-73. PubMed ID: 3891303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of drugs used in juvenile arthritis.
    Skeith KJ; Jamali F
    Clin Pharmacokinet; 1991 Aug; 21(2):129-49. PubMed ID: 1884567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary excretion of drugs in man.
    Rollins DE; Klaassen CD
    Clin Pharmacokinet; 1979; 4(5):368-79. PubMed ID: 389528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulindac metabolism: the importance of an intact colon.
    Strong HA; Warner NJ; Renwick AG; George CF
    Clin Pharmacol Ther; 1985 Oct; 38(4):387-93. PubMed ID: 4042521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.